Sorrento Therapeutics (SRNE) Stock Chart & Stock Price History $0.0013 0.00 (-45.83%) As of 03:50 PM Eastern Add Compare Share Share Chart Stock AnalysisChartCompetitorsFDA EventsInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Sorrento Therapeutics Stock Price Performance The Sorrento Therapeutics (SRNE) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has decreased 86.46%, with a year-to-date return of 160.00%. In the past month, the stock has decreased 38.10%, reflecting recent market activity. As of the latest close, Sorrento Therapeutics traded at $0.00 with a market cap of $1.32 million and volume of 78,192 shares. Five years ago, the stock traded at $7.94, representing a 99.98% decrease over that period. At the time, it had a market cap of $1.69 billion and a volume of 19.83 million shares. Receive SRNE Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-7.14%1 Month Performance-38.10%3 Month Performance+44.44%Year-To-Date Performance+160.00%1 Year Performance-86.46%5 Year Performance-99.98% SRNE Stock Chart for Monday, July, 14, 2025 SRNE Chart by TradingView Sorrento Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/14/2025$0.00$0.00-45.83%$0.00$0.00257,339 shs$717,000.0007/11/2025$0.00$0.00+84.62%$0.00$0.0078,192 shs$1.32 million07/10/2025$0.00$0.00-7.14%$0.00$0.0099,888 shs$717,000.0007/09/2025$0.00$0.00$0.00$0.0098,626 shs$772,000.0007/08/2025$0.00$0.00+7.69%$0.00$0.0066,281 shs$772,000.0007/07/2025$0.00$0.00$0.00$0.00100,936 shs$717,000.0007/04/2025$0.00$0.00$0.00$0.00593,018 shs$717,000.0007/03/2025$0.00$0.00-7.14%$0.00$0.00593,018 shs$717,000.0007/02/2025$0.00$0.00$0.00$0.0069,320 shs$772,000.0007/01/2025$0.00$0.00$0.00$0.0022,913 shs$772,000.00 Get the Latest News and Ratings for SRNE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 06/30/2025$0.00$0.00-36.36%$0.00$0.00146,709 shs$772,000.0006/27/2025$0.00$0.00-18.52%$0.00$0.00510,020 shs$1.21 million06/26/2025$0.00$0.00+22.73%$0.00$0.0099,478 shs$1.49 million06/25/2025$0.00$0.00$0.01$0.00144,745 shs$1.21 million06/24/2025$0.00$0.00$0.00$0.00164,043 shs$1.21 million06/23/2025$0.00$0.00$0.00$0.0024,843 shs$1.21 million06/20/2025$0.00$0.00+4.76%$0.01$0.00130,217 shs$1.21 million06/19/2025$0.00$0.00$0.00$0.00378,612 shs$1.16 million06/18/2025$0.00$0.00-16.00%$0.00$0.00378,612 shs$1.16 million06/17/2025$0.00$0.00$0.01$0.0085,199 shs$1.38 million06/16/2025$0.00$0.00+19.05%$0.00$0.00115,115 shs$1.38 million06/13/2025$0.00$0.00$0.00$0.0069,045 shs$1.16 million Related Companies PainReform Stock Chart Virax Biolabs Group Stock Chart Jaguar Animal Health Stock Chart Aditxt Stock Chart Onconetix Stock Chart Palatin Technologies Stock Chart Aspira Women's Health Stock Chart Alzamend Neuro Stock Chart Conduit Pharmaceuticals Stock Chart Heatwurx Stock Chart Receive SRNE Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:SRNE) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn extra $1,000 per month?A little-known Title 15 provision could let you collect instant payouts — $100 to $1,000 — directly from your ...TradeSmith | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
